Could CAR t-cells tame myasthenia gravis? early trial launches
Disease control
Recruiting now
This early-phase study tests a new treatment called anitocabtagene autoleucel (anito-cel) for people with generalized myasthenia gravis, a condition that causes muscle weakness. Anito-cel is a type of CAR T-cell therapy that targets BCMA, a protein on certain immune cells. The tr…
Phase: PHASE1 • Sponsor: Arcellx, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC